Skip to main content

Table 2 Clinical characteristics

From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

 

Low-risk PV (n = 1033)

High-risk PV (n = 1823)

All patients (N = 2856)

Comorbid condition, n (%)

 Hypertension

445 (43.1)

1185 (65.0)

1630 (57.1)

 Chronic pain

187 (18.1)

473 (25.9)

660 (23.1)

 Diabetes (type 2)

104 (10.1)

396 (21.7)

500 (17.5)

 Osteoarthritis

102 (9.9)

366 (20.1)

468 (16.4)

 Cancer (excluding leukemia and MM)

66 (6.4)

381 (20.9)

447 (15.7)

 Gastroesophageal reflux disease

121 (11.7)

224 (12.3)

345 (12.1)

 Anemia

64 (6.2)

168 (9.2)

232 (8.1)

 Depression

81 (7.8)

123 (6.7)

204 (7.1)

 Anxiety

73 (7.1)

117 (6.4)

190 (6.7)

 Congestive heart failure

6 (0.6)

121 (6.6)

127 (4.4)

 Non-AML leukemia

5 (0.5)

14 (0.8)

19 (0.7)

 MM

1 (0.1)

8 (0.4)

9 (0.3)

Concomitant medication, n (%)

 Cardiovasculara

636 (61.6)

1526 (83.7)

2162 (75.7)

 Corticosteroid (oral or IV)

306 (29.6)

510 (28.0)

816 (28.6)

 Antidepressant

228 (22.1)

369 (20.2)

597 (20.9)

 NSAID

205 (19.8)

314 (17.2)

519 (18.2)

  1. Clinical characteristics evaluated during the preindex period (January 1 to December 31, 2012)
  2. AML acute myeloid leukemia, IV intravenous, MM multiple myeloma, NSAID nonsteroidal anti-inflammatory drug, PV polycythemia vera
  3. aIncludes antihypertensives, statins, antidiabetic medications, anticoagulants, antiplatelet medications, and other lipid-lowering medications